Mi az ára AcelRx Pharmaceuticals, Inc. (ACRX)

AcelRx Pharmaceuticals, Inc. (ACRX) ára $0.922

Mi a AcelRx Pharmaceuticals, Inc. (ACRX piaci tőkésítése)

AcelRx Pharmaceuticals, Inc. piaci tőkésítése (ACRX) $11.68M

AcelRx Pharmaceuticals, Inc. (ACRX) Működési Eredményhányad

AcelRx Pharmaceuticals, Inc. is a specialized biopharmaceutical firm primarily dedicated to advancing and bringing to market medical solutions for managing acute pain. The company's key commercial products include DSUVIA and DZUVEO, which are 30 microgram sufentanil tablets administered under the tongue, intended for treating significant short-term pain. AcelRx also develops ZALVISO, a pre-programmed, patient-managed analgesia system that enables hospital patients experiencing moderate-to-severe acute pain to self-administer sufentanil sublingual tablets for their pain relief. In its development pipeline, AcelRx is progressing ARX-02, which is currently in Phase 2 clinical trials, targeting sudden, intense cancer-related pain in individuals who are tolerant to opioid medications. Another candidate, 4ARX-03, is being investigated for its utility in providing mild sedation and pain relief during various medical procedures that might cause discomfort. Beyond acute pain, AcelRx's investigational portfolio features Niyad, a regional anticoagulant designed for use in external blood circulation systems. Furthermore, LTX-608, a nafamostat formulation for direct intravenous infusion, is being explored as an experimental treatment for a range of conditions, including COVID, severe lung injury (acute respiratory distress syndrome), widespread blood clotting (disseminated intravascular coagulation), and acute pancreatitis. The company was founded in 2005 and initially operated under the name SuRx, Inc., before officially rebranding as AcelRx Pharmaceuticals, Inc. in August 2006. It is headquartered in Hayward, California.

Év	Működési árrés	Változtassa meg
Nincs elég adat a megadott dátumokhoz.

Év

Működési árrés

Változtassa meg

Nincs elég adat a megadott dátumokhoz.

Vállalat	Működési árrés	Működési árrés különbség	Ország
MERCK Kommanditgesellschaft auf Aktien MER.SW	0.00%	-	DE
Merck KGaA MRK.DE	0.00%	-	DE
Takeda Pharmaceutical Company Limited 4502.T	0.00%	-	JP
Galderma Group AG GALD.SW	0.00%	-	CH
Sun Pharmaceutical Industries Limited SUNPHARMA.NS	22.93%	-	IN

Vállalat

Működési árrés

Működési árrés különbség

Ország